2.11

6.22% -0.14

Onkure Therapeutics Inc (OKUR)

Overview News Price History Option Chain Financials Discussions Forecast

Onkure Therapeutics Inc stock is traded at $2.11, with a volume of 326.24K. It is down -6.22% in the last 24 hours and down -27.99% over the past month. OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure-based drug design platform to develop a pipeline of drug candidates aimed at optimizing efficacy and tolerability. The company has multiple programs focused on targeting oncogenic PI3Kα. Its flagship program is OKI-219. The company operates in one operating segment: clinical research.

Previous Close:

$2.25

Open:

$2.26

24h Volume:

326.24K

Relative Volume:

0.57

Market Cap:

$85.45M

Revenue:

Net Income/Loss:

$-58.75M

P/E Ratio:

-0.4876

EPS:

-4.327

Net Cash Flow:

$-50.79M

1W Performance:

-8.26%

1M Performance:

-27.99%

6M Performance:

-53.22%

1Y Performance:

-28.96%

1-Day Range:

$2.09

$2.28

1-Week Range:

$2.09

$2.47

52-Week Range:

$2.09

$5.38

Onkure Therapeutics Inc Stock (OKUR) Company Profile

Name

Onkure Therapeutics Inc

Sector

Healthcare (1051)

Industry

Biotechnology (593)

Phone

(720) 307-2892

Address

6707 WINCHESTER CIRCLE, SUITE 400, BOULDER

Employee

Twitter

Next Earnings Date

2026-11-05

Latest SEC Filings

OKUR's Discussions on Twitter

Compare OKUR vs VRTX, MRNA, REGN, ARGX, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
OKUR Onkure Therapeutics Inc	2.11	85.45M	0	-58.75M	-50.79M	-4.327
VRTX Vertex Pharmaceuticals Inc	508.74	128.95B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	236.50	94.42B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	796.35	81.99B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	846.50	53.23B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	374.30	42.34B	5.76B	514.49M	1.10B	4.4813

Onkure Therapeutics Inc Stock (OKUR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-30-25	Initiated	Evercore ISI	Outperform
Dec-05-24	Initiated	Leerink Partners	Outperform
Oct-10-24	Initiated	Oppenheimer	Outperform
Dec-15-23	Downgrade	H.C. Wainwright	Buy → Neutral
Dec-15-23	Downgrade	Jefferies	Buy → Hold
Dec-15-23	Downgrade	Leerink Partners	Outperform → Market Perform
Dec-14-23	Downgrade	BofA Securities	Buy → Underperform
Dec-14-23	Downgrade	Ladenburg Thalmann	Buy → Neutral
Dec-14-23	Downgrade	Piper Sandler	Overweight → Neutral
Dec-14-23	Downgrade	Robert W. Baird	Outperform → Neutral
Dec-14-23	Downgrade	William Blair	Outperform → Mkt Perform
Nov-15-23	Initiated	William Blair	Outperform
Aug-28-23	Initiated	H.C. Wainwright	Buy
Jul-03-23	Initiated	BofA Securities	Buy
Sep-19-22	Resumed	H.C. Wainwright	Buy
Jan-27-22	Initiated	Robert W. Baird	Outperform
Dec-21-21	Initiated	H.C. Wainwright	Buy
Nov-22-21	Initiated	Ladenburg Thalmann	Buy
May-04-21	Initiated	Jefferies	Buy
May-04-21	Initiated	Piper Sandler	Overweight
May-04-21	Initiated	SVB Leerink	Outperform

View All

Onkure Therapeutics Inc Stock (OKUR) Latest News

Sep 26, 2026

OnKure Therapeutics president and CEO Saccomano sells $258 in stock - Investing.com

Sep 26, 2026

OnKure Therapeutics CFO Jason Leverone sells $898 in stock - Investing.com

Sep 26, 2026

Form 4 Onkure Therapeutics Inc For: 26 September By Investing.com - Investing.com Nigeria

Sep 26, 2026

OnKure Therapeutics CFO Jason Leverone sells $898 in stock By Investing.com - Investing.com Nigeria

Sep 26, 2026

OnKure Therapeutics CFO Jason Leverone sells $898 in stock By Investing.com - Investing.com UK

Sep 26, 2026

Sep 12, 2026

Insiders' US$16.6m Investments In Red Following OnKure Therapeutics' US$19m Dip In Market Value - simplywall.st

Sep 12, 2026

Aug 31, 2026

OnKure management will hold one-on-one investor meetings in New York - Stock Titan

Aug 31, 2026

Aug 23, 2026

OnKure (OKUR) Session: Ends Up by 0.25% at $3.94 in the Latest Reading; Key Range: Traders Can Monitor the $3.74-$4.14 Range in Latest TradingChannel Projection - vinanet.vn

Aug 23, 2026

Aug 14, 2026

Prosight Management, LP Reduces OnKure Therapeutics (OKUR) Stake in Second Quarter - GuruFocus

Aug 14, 2026

OnKure Therapeutics (OKUR): ADAR1 reports 5.5% stake as GP falls below 5% - Stock Titan

Aug 14, 2026

OnKure Therapeutics (OKUR) investor BVF discloses 8% stake plus 2.15M pre-funded warrants - Stock Titan

Aug 14, 2026

OnKure Therapeutics (OKUR) sees 3.6% passive stake reported by Trails Edge - Stock Titan

Aug 14, 2026

Oppenheimer Adjusts OnKure Therapeutics PT to $14 From $30, Maintains Outperform Rating - marketscreener.com

Aug 14, 2026

Aug 13, 2026

OKUR Q2 2026 Earnings: Narrower-Than-Expected Loss Points to Cost Discipline at Clinical-Stage BiotechEstimate Dispersion - vinanet.vn

Aug 13, 2026

OKUR Q2 2026 Earnings: Narrower-Than-Expected Loss Beats Estimates by 43.19%Revenue Recognition Risk - Vinanet

Aug 13, 2026

OnKure Reprices Underwater Stock Options to Boost Retention - TipRanks

Aug 13, 2026

Aug 10, 2026

Prosight entities report 2.4% OnKure Therapeutics (OKUR) stake in 13G/A - Stock Titan

Aug 10, 2026

Aug 08, 2026

OnKure Therapeutics (OKUR) Holds Steady at $4.14 as Biotech Consolidates Within Tight RangeEarnings Sentiment - dars.gov.et

Aug 08, 2026

OnKure Therapeutics (OKUR) Holds Steady at $4.14 as Biotech Consolidates Within Tight RangeTRIN Signal - vinanet.vn

Aug 08, 2026

Aug 07, 2026